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ABSTRACT
A MINIMALLY INVASIVE ASSAY
DETECTS BRCA1 AND BRCA2 PROTEIN TRUNCATIONS
INDICATIVE OF THE PRESENCE OF
A GERMLINE MUTATION
SEPTEMBER 2000
TIMOTHY J. BYRNE, B.S. UNIVERSITY OF MASSACHUSETTS AMHERST
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Wesley R. Autio
Family members with a heritable mutation in the BRCA1 or BRCA2 gene have
up to an 85% life-long risk of contracting one or more of the cancers associated with a
genetic alteration to these genes. The inheritance risks of a BRCA alteration to first and
second-degree relatives of affected individuals are 50% and 25%, respectively.
Currently, members from high-risk families can be tested for the presence of BRCA 1 or
BRCA2 mutations by gene sequencing of blood cell DNA. This test is expensive and
generally is not reimbursed by insurance carriers.
Over 85% of BRCA 1 and BRCA2 mutations are reported to result in the
production of a truncated protein, from which the carboxy terminal end sequences ot their
respective protein is missing.

In preliminary studies, using antibodies specifie for the amino acid terminal or the
carboxy terminal ol the BRCA1 protein, we demonstrated that immunohistochemical
analysis of surgical specimens, consisting of matched ovarian tumor and normal
uninvolved tissue, identified BRCA1 protein truncations in two matched samples. Each
BRCA1 protein truncation was shown to be indicative of the presence of a BRCA1
germline mutation.
Human buccal cells were then investigated as a minimally invasive cell source for
this assay. Buccal cells were shown to express BRCA1 and BRCA2 protein
immunohistochemically using distinct antibodies for the BRCA1 and BRCA2 protein
terminals. Transcription of the BRCA1 and BRCA2 gene within buccal cells was also
shown to occur by RT-PCR.
A double blind study was then conducted using blood DNA and buccal cells
collected from thirteen high-risk patients for carrying a germline BRCA1 or BRCA2
mutation. Mutation analysis (PCR, SSCP, and gene sequencing) was performed on
DNA. Immunohistochemical analysis for the BRCA1 and BRCA2 protein was
performed on cytospun deposited buccal cells. The buccal cell assay correctly predicted
the presence of six germline BRCA1 mutations, three germline BRCA2 mutations, and
three with no mutations. One predicted germline BRCA2 mutation did not correlate with
DNA sequencing results. Based on these results, this assay exhibited a 100% negative
predictive value and 90% positive predictive value.
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CHAPTER 1

OVERVIEW AND REVIEW OF LITERATURE

1.1 Overview
Family members with a heritable mutation in the BRCA1 or BRCA2 gene have
up to an 85% life-long risk of contracting one or more of the cancers associated with a
genetic alteration to these genes. Many types of carcinomas are associated with the loss
of normal function of these two genes. BRCA1 and BRCA2 share similarities and
differences with respect to location and tissue where these malignancies develop. Both
genes are strongly associated with breast, ovarian and prostate cancer. However,
increased risk for colon cancer is associated with BRCA1 only. Male breast cancer,
pancreatic cancer, laryngeal cancer, hepatocellular cancer and ocular melanoma are
associated with BRCA2. The risk for contracting each of these types of cancer varies
greatly. For first degree female relatives (mother, sisters, daughters) carrying the same
gene mutation, there is an 85% lifetime risk for breast cancer, 26%-85% risk of
developing ovarian cancer, and a four-fold increased risk of developing colon cancer.
Other cancers that have been associated with BRCA mutations require further study to
ascertain the cancer risk conferred by each.
The inheritance risks of a BRCA alteration to first and second-degree relatives of
affected individuals are 50% and 25%, respectively. Currently, members from high-risk
families can be tested for the presence of BRCA1 or BRCA2 mutations by gene
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sequencing of blood cell DNA. This test is expensive. The current cost is approximately
$l,200/gene for each family member, and generally is not reimbursed by insurance
carriers.
Over 85% of BRCA1 and BRCA2 mutations are reported to result in the
production of a truncated protein, from which the terminal end sequences (i.e. carboxy
terminus, C-terminus) of their respective protein is missing (6, 17, 35, 36). These gene
mutations are in the form of insertions, single base alterations, single base deletions, or
multiple base deletions that cause a frame shift that results in a premature stop codon.
The premature stop codon produces truncation of the protein consequent to the presence
of the gene mutation.
Amino acid sequencing of the BRCA1 and BRCA2 proteins, deduced from the
availability of the gene sequence, has allowed for the development of peptide sequences.
These peptide sequences have been used as immunogens to raise a series of antibodies
capable of detecting specific regions of the BRCA1 or BRCA2 protein.
In preliminary studies, using antibodies specific for the amino acid terminal or the
carboxy terminal of the BRCA1 protein, we demonstrated that immunohistochemical
analysis of surgical specimens, consisting of matched ovarian tumor and normal
uninvolved tissue, identified BRCA1 protein truncations in two matched samples. Each
BRCA1 protein truncation was also shown to be indicative of the presence of a BRCA1
germline mutation.
Human oral buccal cells provide a non-invasive source of normal nucleated cells
that express the BRCA1 and BRCA2 protein. Heritable BRCA mutations are contained
within every nucleate cell.
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Buccal cells are easily collected with a cotton swab, deposited in a liquid medium
by the test subject and transferred to the research laboratory for testing.
This immunohistochemical test is based on the hypothesis that cells of a BRCA1
or BRCA2 germline mutation carrier will express differences in antibody reactivity of
one or both terminal regions of a BRCA protein. Non-germline mutation carriers will
not. An imbalance between the end terminus regions, as measured by differences in
antibody reactivity, would be indicative of a truncated protein possibly resulting from a
gene alteration.

1.1.1 Hypothesis
The hypothesis of this study was that carriers of a BRCA1 or BRCA2 germline
mutation that results in a truncated BRCA1 or BRCA2 protein, could be detected by
conducting immunohistochemical analysis of the BRCA1 or BRCA2 protein using
buccal cells collected from their oral mouth cavity.
To test this hypothesis a double blind study was conducted using
immunohistochemical analysis of buccal cells and genetic analysis of cell DNA. Buccal
cell samples and peripheral blood were collected from patients selected from the genetic
counseling services at Baystate Medical Center in Springfield, Massachusetts, following
their signed consent. Thirteen high-risk individuals with a significant family history of
breast and/or ovarian cancer were studied.
Immunohistochemical analyses of BRCA1 and BRCA2 were conducted on
cytospin deposited buccal cells using antibodies directed against their respective Nterminal and C-terminal amino acids.
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Mutation analysis was conducted using single stranded conformational
polymorphism (SSCP). Using this technique, gel electrophoresis showed differences in
gene sequences by alterations in single stranded DNA migration patterns. This was
followed by gene sequencing of all coding exons for BRCA1 and/or BRCA2 in which
polymorphisms were detected. In some instances, direct gene sequencing was conducted
by commercial laboratories. Results from genetic analysis and immunohistochemical
analysis were then compared.

1.1.2 Objective
The objective of this study was to develop an inexpensive, minimally invasive
method to screen individuals for BRCA1 and BRCA2 germline mutations to identify all
members of these families, males and females, who may be at risk for passing a heritable
mutation to their offspring.

1.2 Literature Review

1.2.1 Epidemiology of BRCA1 and BRCA2
It is estimated that over 200,000 women develop breast or ovarian cancer in the
United States annually (1). Of these, 5%-10% (10,000-20,000 cases annually) will be
caused by mutations in either the BRCA1 or BRCA2 gene (2). Extensive studies of
breast cancer families as well as of breast and ovarian cancer families have resulted in
the isolation of these two genes (3,4). Both BRCA1 and BRCA2 have been
independently linked with heritable breast and/or ovarian cancer (3,5) and have also been
associated with one or more of the following cancers: colon, prostate, pancreatic,
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laryngeal, hepatocellular, and ocular melanoma (13, 14, 67, 92, 93, 94, 95,101,115, 116).
The mutated forms of these genes do not directly cause cancer, but confer an increased
risk of cancer development. It is generally believed that these genes act as tumor
suppressor genes, and that alterations of both maternal and paternal alleles for either one
of these genes is required for the development of cancer (Knudson two hit hypothesis, 6).
Individuals with a heritable BRCA1 or BRCA2 gene mutation carry one copy of the
altered form of this gene in every nucleated cell of their body. Such individuals may
develop cancer if the corresponding normal BRCA allele is altered within a specific
tissue (breast, ovary, colon, prostate, etc.). Individuals with a germline mutation are one
"hit" closer to developing cancer than the population at-large. Because of this,
individuals with germline BRCA1 or BRCA2 mutations tend to be younger at age of
diagnosis, and are more likely to experience multiple primary tumors involving several
organ systems (e.g. bilateral disease, or primaries involving colon, breast and/or ovaries).
Families with BRCA1 or BRCA2 gene mutations represent 80- 90% of all cancer
family syndromes associated with breast and/or ovarian cancer (62-66). First-degree
female relatives (mother, sisters, daughters) of gene carriers are at 50% risk of carrying
the same gene mutation. Female mutation carriers have up to an 85% lifetime risk of
developing breast cancer, 26%-85% risk of developing ovarian cancer, and a four-fold
increased risk of developing colon cancer (BRCA1) (63-66). Male carriers with a
mutated BRCA1 gene are at increased risk of developing colon and prostate cancer, and
male breast cancer for those with a BRCA2 mutation (2). Other associated cancers may
place males and/or female carriers at modestly elevated risk relative to the general
population (65, 66).
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Recently, several studies have investigated the role of BRCA1 and BRCA2 gene
mutations in seemingly sporadic breast or ovarian cancer as well as the prevalence of
BRCA mutations in specific populations. These studies show that individuals with
sporadic disease are more likely to carry a germline (heritable) BRCA gene mutation if
they are: 1. younger age at diagnosis (<45 years of age at diagnosis of ovarian cancer,
<40 years of age at diagnosis of breast cancer); 2. if they have bilateral disease or, 3. if
they are of Ashkenazi Jewish ancestry (6-16). Two studies have demonstrated that
approximately 2% of the Ashkenazi Jewish population carry a BRCA1 mutation (16-20).
In addition, BRCA1 gene alterations have been detected in approximately 50% of
ovarian cancers, although only a fraction of these cancers are heritable in nature (17-19).

1.2.2 Pathology Of Breast Cancer Tumors In Germline BRCA Mutation Carriers
The pathology of breast cancers in predisposed women differs from that of
sporadic cases. Differences also exist between carriers of germline BRCA1 and BRCA2
mutations. In general BRCA 1-associated breast cancers have been reported as highly
proliferating tumors (53). Correlation between mutation type and disease phenotype has
also been reported for another autosomal dominant condition, neurofibromatosis type 2
(106). In this study, symptoms were most severe when there was a truncation mutation.
The majority of heritable BRCA1 and BRCA2 mutations result in protein truncations
within the conserved terminal regions of their respective proteins. These have also been
categorized as highly proliferative tumors (56, 74, 82, 83, 85, 91, 94). This tumor type
segregates as a genetic trait in BRCA families (53, 54) and also shows a strong
genotype-phenotype correlation. Within BRCA-mutation carriers, breast tumors
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removed from BRCA1 mutation carriers showed greater pleomorphism and higher
mitotic count than similar tumors derived from carriers of a BRCA2 mutation (56, 82,
83, 85, 91, 94). These findings suggest that breast cancers due to BRCA1 mutations
have a different natural history and possible disease progression than cancers due to
BRCA2 mutations or apparent sporadic forms of cancer. This would allow for
identification based upon visual differences (34, 54

1.2.3 Molecular Biology Of Tumors From Germline BRCA Mutation Carriers
Studies of tumors removed from patients with germline BRCA1 or BRCA2
mutations are reported to display loss of heterozygousity (LOH) (7, 26, 27, 29, 30, 57,
118-121). Many times LOH reportedly occurs at the locus that encodes the cystein rich
RING finger motif which binds zinc, as well as at other highly conserved domains (12,
56, 41, 70). Zinc-binding domains are defined as a series of cysteine and histidine
residues and are believed to mediate protein-protein and protein-DNA interactions.
These investigators suggested that BRCA products play a role as tumor suppressor
genes. Other studies support this hypothesis by showing that BRCA1 negatively
regulates the proliferation of mammary epithelial cells (58) and is involved in
differentiation in multiple tissues in response to ovarian hormones (56). Adding to this
evidence are reports showing that both genes encode nuclear and cytoplasmic proteins
with cell cycle-regulated expression patterns that colocalize in multiple tissues during
proliferation and cell differentiation (82).
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1.2.4 Common Features of BRCA1 and BRCA2
BRCA1 and BRCA2, while appearing sequentially unrelated structurally, have
much in common: a translational start-site for each gene is located in exon 2; exon 11
contains over 50% of the codons for the amino acid sequence; and both genes code for
an exceptionally large, highly charged protein (3). BRCA1 codes for 1863 amino acids
and BRCA2 codes for 3418 amino acids. Comparison of the amino acid sequence of
human BRCA1 and BRCA2 to the amino acid sequence of these same genes in mouse,
indicates that the respective proteins share approximately 60% identity between these
two species (70, 71, 74). Because most tumor-suppressor genes are more highly
conserved across species than BRCA1 and BRCA2, this suggests that both genes may be
evolving at the same rate.
Both BRCA messages also appear to be induced during the late G1 early S phase
of the cell cycle (52, 58, 76, 77, 90), with concordant expression of the protein (47, 80,
81). Another similarity was noted in a study of expression patterns for each of these
proteins in developing mouse embryos. Both BRCA1 and BRCA2 are most highly
expressed in rapidly dividing tissues undergoing differentiation.
Up-regulation of the steady-state level of both messages was also reported in
breast tissue during puberty, pregnancy and lactation (56, 74, 82, 83, 85, 91). However,
BRCA1 and BRCA2 mRNA expressions are differentially regulated by sex hormones.
When testosterone levels increased in the testes, up-regulation of BRCA2 was delayed
relative to BRCA1. In the breast, ovarian hormones caused an increase in BRCA1
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mRNA only, with no effect observed on BRCA2 (82). Still, the many commonalities
shared by these two genes indicate that they may function in the same or overlapping
biological pathways.

1.2.5 Molecular Biology and Functional Properties of BRCA1 and BRCA2

1.2.5.1 Granin-Like Properties
The discovery that the BRCA1 protein exhibits properties of a family of proteins
called granins gave researchers clues to some possible BRCA1 functions and provided
conceptual ideas for studying the location of the BRCA1 protein within the cell. Granins
are a secreted protein located in secretory granules of neuroendocrine tissues, some of
which are estrogen regulated (59, 60, 61, 68). Other post-translation granin
characteristics are protein modification by sulfation, glycosylation or phosphorylation
and peptide activation following proteolytic cleavage (60, 61).
It does not seem the case, however, that BRCA1 functions exclusively as a granin.
There are also discrepancies in the literature concerning the BRCA1 protein size and
cellular location. Two separate research teams report the BRCA1 protein to be a
190KDa. regulated, secretory protein (50, 51). In one of these reports the BRCA1
protein's functional mechanism is referred to as unique for tumor suppressor gene
products (51). Other investigators report that the BRCA1 protein is a 220KDa, nuclear,
phosphoprotein (46, 47,49, 52). The greatest expression and phosphorylation of
BRCA1 reportedly occurs in the S and M cell phases (47, 48). While similar antibodies
were used in all of these investigations (C20, D20, OP92, OP93), differences
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in results were explained by cross reactivity with estrogen growth factor receptors
(EGFR), aberrant subcellular localization (48) and different fixation techniques (45).
Another study reports finding that BRCA1 expression is indirectly responsive to
estrogen resulting from mitogenic activity (52). This would be inconsistent with a
hormonally regulated granin. We tested buccal cells for cross reactivity with EGFR and
found none. This showed that buccal cells do not contain EGFR and allowed us to
consider these cells as a viable test source. The antibodies used in this study are similar
to those used in previous reports.

1.2.5.2 Transcriptional-Regulation and BRCA1 and BRCA2
Many studies of the BRCA1 and BRCA2 genes have concentrated on mitotic
transcription and translation aspects to determine how and where BRCA product(s)
function on the cellular level. Both BRCA1 and BRCA2 contain putative transcription
activation domains. In BRCA2 a region encoded by exon 3 contains a 45-amino acid
portion with similarities to a transcription factor c-jun, known to activate transcription in
yeast when fused to the lexA DNA-binding domain (107, 108). A COOH terminus in
BRCA1 has been reported as a binding module for GAL4 required for transcription of
the GAL reporter gene (90, 99). Studies with knockout mice (mice with specific,
engineered gene deletions) revealed that loss of Brcal or Brca2 regulation results in
overexpression of gene p21 and/or gene p53. This resulted in death during early
embryonic development (87, 117). This study clearly suggests that the BRCA genes
may control cell growth and prevent cell proliferation by actions that regulate
transcription and/or translation of other gene products.
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An in vivo study found that an interaction occurred between the N-terminal region
of the BRCA1 protein and a second protein referred to as BARD1. Much homology to
conserved domains near the BRCA1 protein's C-terminal was found in the BARD1
protein. This consisted of a COOH-terminal domain present as two tandem repeats
termed BRCT (96-98). Missense mutations that segregate with a predisposition to breast
cancer were shown to disrupt the BRCA1-BARD1 interaction. These mutations are
associated with disruption of the RING finger structural motif as well (55). This
suggests that protein interaction may be important for BRCA1-mediated tumor
suppression. All these studies place emphasis on the importance of the BRCA1 and
BRCA2 termini regions and their continued integrity for proper protein functioning. The
evolutionary conserved nature of these regions has been shown to hold for other
mammals as well (12). This too, argues for their importance in mammary cell growth
and would allow for greater specificity in their detection.

1.2.5.3 DNA Repair Involves BRCA1 and BRCA2
Initially, high levels of expression patterns of the hRAD51 protein along with both
BRCA1 and BRCA2 in testes, ovaries and thymus (82, 83), all areas important for
meiosis and recombination, suggested that BRCA genes may be involved in DNA
damage response. While BRCA1 and BRCA2 now clearly appear to play important
roles in cellular response to DNA damage, each does so through different pathways.
BRCA2 is reported to interact directly with hRAD51. This protein catalyzes ATPdependent DNA strand exchange reactions and is one of five known human homologs of
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the prototypical E. coli recombination and repair protein RecA (113, 117). The area on
BRCA2 that is responsible for this is located on exon 11. This domain consists of 8 or 9
copies of a 30-80 amino acid repeat termed BRC (72).
This area has been highly conserved relative to the rest of the BRCA2 sequence,
suggesting that the BRC region is important for normal functioning (73).
In mouse studies, various mutations within this area have resulted in phenotypic
differences in disease expression. When coding sequence were deleted upstream of all
suspected putative interaction domains, all mice died while still in the embryonic stage
(87, 109, 110). Mice with mutations that disrupted a small portion, 3 repeats, (112) or
large portion of this region, 6 repeats, (111) survived to birth and past weaning. Mice
with fewer functional repeats exhibited defects that include absence of germ cells,
stunted growth and increased risk of lymphoma.
Although these studies were conducted in mice, they still elucidate the significance
of the BRCA2-hRAD51 (MmRad51 in mice) interaction domain. By contrast, BRCA1
reportedly does not interact directly with hRAD51, although both BRCA1 and hRAD51
may be present in the same multiprotein complex. In mitotic cells BRCA1, hRAD51 and
BRCA2 co-localize to discrete nuclear foci during the S phase, whereas in meiotic cells,
this protein complex associates with axial elements along developing synaptic complexes
(38, 86, 89, 88, 114,). These data suggest that this protein complex may be the activation
of double-break repair and/or homologous recombination. BRCA1 appears to function
in the DNA repair mechanism by direct association with the RNA polymerase II
transcriptional apparatus known as a holoenzyme. Although the role that BRCA1 plays
here is not clearly defined, holoenzymes are intimately involved with many DNA repair
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elements (38, 101). Also, within the carboxy-terminal region of BRCA1 a TP53 binding
region referred to as BRCT has been identified. BRCT repeats are conserved motifs
found in many proteins and are reportedly involved with DNA repair and metabolism
(70, 71). This domain was found to be important for substrate interaction to allow
activation of the GAL gene (90, 99). Collectively, these data are interpreted to support a
transcriptional role for BRCA1 in DNA repair. These studies also indicate the BRCA
genes are directly and indirectly involved with production and activation of other
proteins that play additional regulatory roles in cell growth and differentiation.

1.2.5.4 Splice Variants and BRCA1
Recent efforts directed toward molecular characterizations of BRCA1 have found
functional BRCA1 splice variants in mRNA and protein products. This may help
explain some differences in protein localization reported in the literature and also
suggests that each gene has multiple functions. Splice variants have been found in exon
11 and 9+10. Each is predicted to encode an 80-85KDa BRCA1-derived protein (44).
Through RNA probe titration and RT-PCR, (reverse transcription-polymerase chain
reaction) BRCA1 and a BRCA1 splice variant, delta-1 lb, have been shown to be co¬
expressed in many cells, however, the splice variant of BRCA1, delta 1 lb however, is
reduced or absent in several breast and ovarian tumor lines. This has been interpreted to
suggest that each protein has a distinct role in regulating cell growth (43). Other splice
variants have also been characterized and indicate cytoplasmic and nuclear localization
(42). Results from this same study also suggest that transcriptional factors coupled to
phosphorylation by complexes associated with the zinc RING finger domain are
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necessary for major protein-protein BRCA1 interactions (42). Mutations in the RING
finger domain may prevent cell cycle regulation, allowing for cell proliferation.
Aprelikova et al. (37) showed that BRCA1 protein levels did not change with the
addition or deprivation of growth factor in cell line MCF10A. This suggests that
BRCA1 may have an indirect role in cell cycle regulation of some cell lines. With this
assay test, some splice variants may give false negatives. Approximately 15% of
reported mutations do not result in protein truncation. This could occur by mutations
contained within the removed portions while both protein-end terminals remain intact.
In this study, this possibility was taken into consideration by using SSCP and gene
sequencing to verily all immunohistochemical results.

1.2.5.5 Mutations In BRCA1 and BRCA2
While high frequencies of specific mutations in each gene have been found in
certain ethnic populations (6), the vast majority of mutations reported to date are
distributed over their whole coding sequences. In BRCA1, over 100 mutations have been
identified. This list includes missense mutations, frameshifts and splice-site alterations
(2, 7). In BRCA 2, however, the majority of mutations described involve microdeletions
of 1-6 nucleotides that have resulted in missense and ffameshift mutations only (4). This
large assortment of mutations, coupled with the formidable size of each of these genes
(BRCA 2 spans approximately 70 kb of genomic DNA; BRCA 1 is distributed over 100
kb, 4, 7), makes detection of mutations and gene sequencing very labor intensive,
expensive and technically challenging.
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In many male breast cancer patients, BRCA2 germline mutations are found in
families without a history of the disease (67, 102-105). In this study, 34 male breast
cancer cases were analyzed. Seven were found to contain germline BRCA2 mutations
and only one of these seven cases had a positive family history.
A few identified cancer families have been linked to the BRCA1 gene region
without any BRCA1 mutations being found. This suggests some form of disruption of a
regulatory nature that affects normal transcription and/or translation. The presence of a
RING finger (zinc-binding) domain near the amino terminal of BRCA1 supports this
theory (12, 56, 41). This type of protein conformation is a binding site that is associated
with regulating DNA transcription (12, 56).
Three BRCA1 regions have been identified as potential nuclear localization
signals. Transport through the nuclear pore complex requires a nuclear localization
sequence(s) (NLS) in the transport substrate. Mutations induced to each region revealed
two putative regions that resulted in cytoplasmic localization of the BRCA1 protein (40).
This supports the possibility that defects in the cellular pathways involving NLS can
result in mislocation of the BRCA1 protein and disrupt transcriptional regulation of other
genes.
In a separate study, the C-terminal region comprising exons 16-24 of BRCA1,
called BRCT, was reported to bind to a specific DNA domain of the GAL reporter gene.
These binding proteins activate transcription of the GAL gene from promoters
containing a specific GAL4 site located on BRCA1 (39). This function was suppressed
when a clinically introduced missense mutation caused loss of the wild-type
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BRCA1-BRCT domain (90, 99). Mislocation of the BRCA proteins resulting from
defects in the cellular pathway may not be detected immunohistochemically but would
have been elucidated in our study using SSCP and gene sequencing.
Many germline mutations that interrupt protein binding are clinically relevant
because of their implications on the transcriptional process and protein production. This
greatly broadens the regulatory functions for the BRCA1 and BRCA2 protein. The
categorizing of cause and effect for specific BRCA mutations will allow for a better
understanding of their roles on the cellular level and how cancers associated with a
disfiinctional BRCA1 or BRCA2 gene can develop.
One feature common to most BRCA1 and BRCA2 mutations is that they produce a
truncated protein that results from a premature stop codon in the amino acid sequence.
Immunohistochemical analysis of normal (non-tumor) tissue from carriers of this type of
mutation could reveal a quantitative decrease in carboxy terminal antibody binding
relative to quantitative antibody binding to the amino terminal (figure 1). A similar
assay performed on muscle biopsies has been shown to have useful clinical applications
in distinguishing between truncated dystrophin protein products associated with
Duchenne's muscular dystrophy and Becker's muscular dystrophy, which contain an
untruncated form of the same protein.
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Figure 1. Diagrammatic representation of anti-BRCAl antibody binding in various
conditions, (a) Antibody binding pattern expected in tissue with two unaltered BRCA1
proteins (i.e. no mutations), (b) Antibody binding pattern expected in tissue in which the
protein of an entire BRCA1 allele has been lost (i.e. tissue or tumor in which the allele is
lost or in which an unstable protein product is produced), (c) Antibody binding pattern
expected in tissue in which one normal allele is present and the other allele contains a
nonsense mutation that produces a stable protein product (i.e. normal tissue with a germline
nonsense mutation or tumor with a sporadic nonsense mutation), (d) Antibody binding
pattern expected in tissue in which one allele contains a nonsense mutation and the other
allele is deleted or in which the second allele contains a different nonsense mutation (i.e.
tumor of individual in lc, or tumor following two sporadic hits) or in which no stable
product is produced. ***—< and >—*** represent immunohistochemically detectable
antibodies directed against the normal amino and carboxy terminal amino acids of BRCA1,
respectively. AAA and CCC represent the normal amino and carboxy terminal ends of
BRCA1, respectively. X represents a nonsense mutation. [ 0 ] represents an absent protein
product. The expected relative antibody binding ratios are depicted to the right.

1.2.5.6 Testing For Germ line BRCA Mutations
The determination of BRCA1 and BRCA2 gene status among high-risk individuals
has generated much interest. Such identification can potentially help triage individuals
from families with known or suspected BRCA mutations into appropriate screening and
management protocols and can assist in enhancing knowledge about this disease.
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The demonstration of a heritable BRCA1 or BRCA2 gene mutation among at-risk
individuals can result in more specific targeting of expensive screening and intervention
protocols.
Individuals from families with known or suspected BRCA mutations, who
themselves have not demonstrated germline mutations, can be spared the cost and
morbidity associated with such protocols and returned to surveillance protocols more
consistent with those individuals' specific risk factors. For individuals with heritable
BRCA mutations, such testing can help better define the natural history of this disease,
as well as the efficacy of current surveillance protocols and the benefit of prevention
regimens, and also may lead to the development of more effective screening, prevention,
and treatment strategies (2).
In light of these potential benefits, testing for BRCA genes has become
commercially available for individuals considered at increased risk (>10%) for carrying
a germline BRCA gene mutation. Unfortunately, the complexity of both the BRCA1 and
BRCA2 genes and the paucity of common mutations has hindered the development of a
simple assay for mutation detection.
Current commercial and investigative methods for mutation analysis include
sequencing of candidate polymorphisms detected by single-strand conformation
polymorphism (SSCP) analysis, clamped denaturing gel electrophoresis, or heteroduplex
analysis, direct DNA sequencing of the BRCA1 and/or BRCA2 genes, protein truncation
tests with surgical samples, and DNA chip technology (20). These techniques are
expensive to develop, are labor intensive, and/or require substantial technical expertise.
As a result, the cost of commercial testing is prohibitive ($1200 for the analysis of one
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gene, $2400 for the analysis of both BRCA1 and BRCA2 genes). In the absence of an
inexpensive screening tool, the development of cost-effective clinical protocols for
individuals at risk for a BRCA gene mutation remains a substantial challenge with
significant benefits to humankind.
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CHAPTER 2

AN ANTIBODY-BASED ASSAY DETECTS BRCA1 MUTATIONS IN
SURGICAL SPECIMENS OF PAIRED OVARIAN TUMORS AND
UNINVOLVED NORMAL TISSUE

2.1 Overview
Breast and ovarian cancers rank second and fourth, respectively, in mortality in
the United States with greater than 200,000 new cases reported each year. A significant
number of these cases can be attributed to alterations in BRCA1, a tumor-suppressor
gene. Over 85% of alterations in the BRCA1 gene result in premature termination of the
BRCA1 protein resulting in truncation.
Using antibodies directed against the amino and carboxy terminal regions of the
BRCA1 protein, immunohistochemical analysis was conducted on paraffin sections of
paired ovarian cancer and normal tissue of ten patients. Mutation analysis, employing
polymerase chain reaction (PCR) and single strand conformational polymorphism
(SSCP) and gene sequencing, was also performed on DNA extracted from liquid
nitrogen, snap frozen sections of paired malignant ovarian tissue and normal uninvolved
tissue from the same ten patients. The tissue samples were selected from a high-risk
population of women who were likely to carry a heritable BRCA1 gene alteration.
Among the ten matched specimens, six tumor specimens revealed a reduction in
BRCA1 C20 and D20 antibody reactivity. BRCA1 mutation analysis of these six tumors
showed intragenetic loss of heterozygosity (LOH) at BRCA1 sites for all six specimens.
From this group of six, two corresponding normal tissue specimens revealed decreased
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BRCA1 C20 antibody reactivity. DNA analysis of the match normal tissue revealed a
germline BRCA1 gene alteration in each of these two tissue specimens. No mutations
were detected in the other four corresponding normal tissue specimens, and BRCA1 D20
and C20 activities were normal. The remaining 4 paired samples showed no reduction in
antibody reactivity, and no BRCA1 gene alterations were found in these ovarian tumors
or their normal, uninvolved tissues.
These results suggest that the degree of BRCA1 antibody reactivity correlates
with BRCA1 gene alteration in both tumor and normal, uninvolved surgical specimens.
An immunoreactivity assay for the BRCA1 amino and carboxy terminals may serve as a
rapid and inexpensive assay for the detection of the presence of BRCA1 gene alterations
in surgical specimens.

2.2 Introduction
Breast and ovarian cancers are among the most common diseases affecting
women today. One out of eight women will develop breast cancer by the age of 85, and
ovarian cancer is the leading cause of cancer deaths resulting from malignancies of the
female reproductive system (1, 233). These cancers rank second and fourth,
respectively, in terms of cancer mortality in American women, with greater than 200,000
new cases reported each year (1). Five to 10% of these carcinomas are thought to result
from a hereditary predisposition with germline mutations conferring autosomal dominant
susceptibility (3).
The mutation and subsequent inactivation of one gene, BRCA1, is believed to
account for 45% of familial breast cancers and 80% of inherited breast and ovarian
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cancer syndromes (2). These individuals have an estimated 84% life-long risk of
contracting breast cancer and 44% risk for ovarian cancer (15,151). While BRCA1
mutations have been implicated in the etiology of heritable breast and ovarian cancers,
little or no conclusive role has been deduced for this gene relative to the sporadic forms
of these diseases. Although 50% of ovarian cancers reportedly show loss of
heterozygosity for BRCA1, low numbers of somatic mutations have been reported for
BRCA1; 5 have been reported for sporadic ovarian carcinomas and none found in
sporadic breast cancer (27, 28, 141).
Etiological differences between heritable and sporadic forms of these cancers
have suggested that phenotypic variations may also exist. Several studies have reported
a large percentage of tumors from BRCA1 mutation carriers to be high-grade and of
medullary or atypical medullary type (142-148). The preponderance of these high-grade
tumors resulted in part from an increased rate of mitosis (142, 143, 148, 152). Also,
estrogen and progesterone receptors are expressed less frequently within BRCA1 tumors
(144-149).
The pathology of breast cancers in predisposed women also differs from that of
sporadic cases. Differences also exist between carriers of germline BRCA1 and BRCA2
mutations. In general, BRCA 1-associated breast cancers have been reported as highly
proliferating tumors (53). Correlation between mutation type and disease phenotype has
been reported for another autosomal-dominant condition, neurofibromatosis type 2
(106). In this study, symptoms were most severe when there was a truncation mutation.
Ihe majority of heritable BRCA1 and BRCA2 mutations result in protein truncatioas
within the coaserved terminal regioas of their respective proteins.
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These have also been categorized as highly proliferative tumors (74, 82-85, 91,
94). Within BRCA-mutation carriers, breast tumors removed from BRCA1 mutation
carriers showed greater pleomorphism and higher mitotic count than similar tumors
derived from carriers of a BRCA2 mutation (82-85, 91, 94). These findings suggest that
breast cancers occuring in carriers or a BRCA1 mutation have a different natural history
and possibly a different disease progression than carriers of a BRCA2 mutation or
apparently sporadic cancers. Potentially, this difference would allow for the
development of a reliable screening tool to detect heritable BRCA1 and BRCA2
mutations based upon visual differences (34, 54).
The multiple roles that BRCA1 and BRCA2 appear to play in DNA maintenance
and repair make them important factors in maintaining genomic stability (155, 156, 166,
167). Chromosome deletion of the wild type allele often results from genetic instability
and is frequently precluded by a BRCA1 or BRCA2 germline mutation. The
surrounding chromosome region also may be affected. This is detected with regional
markers. Deletion of areas on the wild type allele such as this are referred to as loss of
heterozygousity (LOH). When LOH occurs, expression of the wild type allele is lost.
Therefore, LOH is detected by the loss or alteration of expression of 1 allele.
Earlier, DNA analysis of breast tumors revealed LOH of the normal chromosome
at certain genomic regions. These findings suggested that the areas were occupied by
tumor suppressor genes (57, 154). Later, the designations BRCA1 and BRCA2 were
assigned. Although BRCA1 plays a minor role in sporadic forms of breast and ovarian
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cancer. LOH is frequently reported for the BRCA1 locus (12, 26-30, 41, 56, 57, 70, 118121, 149, 150). In carriers of a BRCA1 or BRCA2 mutation, LOH is reported to occur
in 88% of informative, or heterozygous, tumors (157-163).
Since BRCA1 was first cloned and mapped to the long arm of chromosome
17q21 (4), research efforts have focused on identifying genetic lesions and germline
mutations within this gene, and their influence on genetic expression. Over 500 BRCA1
alterations have been reported to date (38). Some of these include missense, ffameshifts
and splice-site alterations. Some have been recurrent, others have been reported only
once (5, 38).
Recently, several studies have investigated the role of BRCA gene mutations in
seemingly sporadic breast or ovarian cancer as well as the prevalence of BRCA
mutations in specific populations. Individuals with no significant family history but with
specific risk factors have been shown to be at increased risk of carrying a germline
(heritable) BRCA gene mutation. The risk factors found to be significant include early
age of onset of disease, bilateral disease, or Ashkenazi Jewish ancestry (15-25). In
addition, while ovarian cancer is rarely the result of direct mutations of the ovary, loss of
heterozygousity (LOH) of the BRCA1 gene has been detected in up to 50% of ovarian
cancers (26-28).
The complexity of the BRCA genes along with the paucity of common mutations
has hindered the development of a simple assay for mutation detection. Both BRCA
genes are large and produce very large proteins. Structurally, the BRCA1 gene contains
24 exons and encodes a protein reportedly 190KDa to 240KDa. The normal functioning
BRCA1 protein is unique. It contains few repetitive regions and has a very specific
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amino acid sequence throughout including the amino-terminal and carboxy-terminal
ends of the protein. While the actual size, location, and function of this protein have
been the subjects of much debate, investigators have generally agreed that greater than
85% of BRCA1 mutations are nucleotide insertions or deletions resulting in frameshift
alterations and the consequent introduction of a premature stop codon (29,30). These
lead to various truncation patterns of the BRCA1 protein. Therefore, most mutated
BRCA1 protein products do not contain the normal, carboxy terminal amino acids.
Current commercial and investigative methods for mutation analysis include
sequencing of candidate polymorphisms detected by single strand conformation
polymorphism (SSCP) analysis, clamped denaturing gel electrophoresis, or heteroduplex
analysis. Also, direct DNA sequencing of the BRCA1 and/or BRCA2 genes, protein
truncation test, and DNA chip technology are also used (29). These techniques are
expensive to develop, labor intensive, and/or require substantial technical expertise. As
a result, the cost of commercial testing is prohibitive.

2.3 Hypothesis
Since most BRCA1 mutations result in protein truncations, it was hypothesized
that such mutations would be detected by immunohistochemical (IH) analysis by using
commercially available antibodies directed against the BRCA1 amino and carboxy
terminals. Specifically, it was postulated that antibodies directed against the amino- and
carboxy-terminal amino acids would demonstrate a quantitative reduction in BRCA1
carboxy-terminal reactivity in tissue carrying most BRCA1 mutations relative to their
normal tissue. To test this hypothesis, we analyzed matched ovarian cancer tissue and
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uninvolved tissue obtained from ten patients, at increased risk for heritable ovarian
cancer. Ovarian cancer was studied, because greater than 50% of sporadic ovarian
tumors are associated with BRCA1 gene alterations. The individuals’ normal tissue
served as a control as such mutations are generally isolated to tumor only and thus not
found in normal tissue. Individuals at increased risk for heritable ovarian cancer were
selected, to potentially identify a subgroup of individuals with a heritable BRCA1
mutation. These individuals possess BRCA1 alterations in involved and uninvolved
tissue. These tissue specimens would help determine whether immunoreactivity of the
BRCA1 protein could predict the presence of germline mutations within normal
uninvolved tissue.

2.4 Objectives
The objectives of this study were to:
1. Collect surgical specimens of tumors and matched uninvolved tissue from high-risk
ovarian cancer patients.
2. Determine whether germline BRCA1 mutations could be detected in normal
uninvolved tissue, using immunohistochemical analysis of the amino and carboxy
terminals of the BRCA1 protein.

2.5 Materials and Methods
Frozen and parraffm embedded, matched ovarian cancer tissue and uninvolved,
normal tissue from individuals with early age of onset (<45 years old) were obtained
through the Gynecological Oncology Group/Cooperative Human Tissue Network
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ovarian tissue bank (Columbus, OH). Primary site cancers not previously treated with
chemotherapy or radiation were used. Patients with early age onset of ovarian cancer
were chosen to increase the probability of receiving samples from patients with heritable
BRCA1 mutations. Ten experimental samples were chosen from an original group of
thirty-eight pairs supplied by the GOG tissue bank. Selection of these ten samples was
based upon BRCA1 expression in their normal uninvolved tissue. Many normal tissue
samples were comprised primarily of fatty tissue that did not express BRCA1 protein.
These were not used.
Genomic DNA was extracted from frozen tissue and tumors using a Puregene
DNA Isolation Kit (Gentra Systems, Inc.). Briefly, cells were lysed using an anionic
detergent while limiting enzyme activity to preserve DNA. RNA was enzymatically
digested and salt precipitation was utilized to remove protein contaminants. Genomic
DNA was then isolated by alcohol precipitation and resuspended in a buffered solution.
Optical density readings were done on all DNA extractions at A26o and A2so to determine
DNA quantity and purity.
For single stranded conformational polymorphism (SSCP) analysis, polymerized
chain reaction (PCR) amplification using genomic DNA was performed with intronbased primers surrounding each of 22 BRCA1 exons. Four overlapping primer sets were
used to examine exon 11. Exons 6 and 7 were amplified as one product (7). BRCA1
primers were synthesized by Midland Reagent Company (Midland, TX). PCR was
carried out in a volume of 50 ul containing lug genomic DNA, 10 mM Tris-HCl (pH
8.3), 1.5 mM MgCl2, 50 mM KC1, 200 uM concentration of each dATP, dTTP and
dGTP, 20 uM dCTP, 1 uCi of labeled [32P] dCTP (6000 Ci/mmol; Amersham, Chic., IL).
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Each primer was 1.0 uM and 0.4 units of Amplitaq Polymerase (Perkin Elmer
Cetus, CT) was used in each reaction. DNA amplification was done using a Perkin
Elmer Cetus 9600 thermal cycler. A 46 cycle 3-temperature cycling program was used
to generate PCR product. The program initiates with 1 minute at 95C. Cycles
commence with 10 sec. at 95C, 10 sec. at 68C, 10 sec at 72C. This was repeated for 4
sets of 4 cycles with 68C descending to 60C in 2C increments every 4 cycles. When
60C was reached, 30 cycles were repeated followed by a single 5 min. at 72C (7).
A modification of an SSCP protocol described by Epstein et al. (232) was used
for detecting BRCA1 gene alterations. A 1 ul aliquot of the PCR product was diluted
into 9 ul of denaturing-loading buffer consisting of 95% formamide, 10 mM NaOH,
0.05% xylene cyanol FF and 0.05% bromophenol blue, by volume. The 10 ul mixture
was heated to 95C for 10 min. and plunged into an ice bath for rapid cooling. A 3 ul
aliquot of this solution was then transferred to a 5% polyacrylamide/bis gel containing
5% glycerol and 0.5X Tris-borate EDTA for electrophoresis. Gels were prerun at 30
watts for 30 min. before loading samples. Upper and lower reservoirs of the gel
apparatus contained 0.5X Tris-borate EDTA buffer. Gels were run at room temperature
for 130 watt hours after which they were transferred to 3mm chromotography paper,
placed in plastic wrap and exposed to reflection autoradiography film (Biomax MR film,
Kodak) for 18 to 24 hours at -70C. Each gel contained PCR product, from a given
primer set, for each individual’s uninvolved tissue and corresponding tumor specimen.
SSCP gels were scored for unique banding patterns and lost bands. Since the PCR
product contained exon and part of the adjacent intronic sequence where variations,
unique bands seen in uninvolved tissues, were scored as polymorphisms.
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As new mutations in ovarian tumors are rare and LOH is common, LOH was
inferred when unique SSCP bands were noted to be absent in the tumor specimens
relative to their corresponding uninvolved normal tissue.
Genomic DNA sequencing was completed using the Amplicycle Sequencing Kit
(Perkin Elmer Cetus, CA). This is a modified version of the Sanger method (232) for
sequencing double stranded DNA (dsDNA) and does not require subcloning and/or
extensive purification prior to sequencing. Sequencing utilized 33P isotope and was
conducted according to the protocol supplied by Perkin Elmer Cetus. Both alleles were
sequenced for each polymorphism identified by SSCP analysis. Reaction cycling was
done in a GeneAmp PCR System 9600 (Perkin Elmer Cetus, CA). Termination reaction
cycling conditions used an initial step of 1 min. at 95C followed by 25 cycles of a 3temperature cycling protocol; 30 sec. at 95C, 30 sec. at 68C and 1 min. at 72C.
Reactions were then arrested by the addition of 4 ul stop solution (the same composition
as that used for SSCP). Sequencing gels consisted of 6 to 8% acrylamide/bis solution,
IX Tris-borate EDTA and 7M urea. Gel solution was passed through a microfilter prior
to use, and all gel glass plates were silonized on one side. Gels were prerun for 30 min.
with IX Tris-borate EDTA buffer at 60-75 watts. Just prior to use, sequencing reactions
were denatured by heating to 90-94C for 3 min. A 3 ul sample of the denatured
sequence solution was dispensed from each sequence reaction and loaded onto the gel.
Gels were run for 2-3 hours at 60-75 watts, cooled, then fixed in a 10% acetic
acid, 10% methanol solution, by volume, for 30 min. to remove urea, and then was
transferred to 3 mm chromotography paper.
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Excess liquid was drained from the gel surface when removed from the solution
to allow for easier transfer. Gels were covered with plastic wrap, backed with a second
sheet of 3 mm chromatography paper and dried in a gel dryer model 583 (Bio-Rad
Laboratories). Sequence ladders were resolved by autoradiographs through direct
contact of dried gels to Biomax MR x-ray film (Kodak, Inc. Rochester, NY). Exposure
time was 24-48 hours at room temperature.
To evaluate each sample utilizing immunohistochemistry, a minimum of two
slide-mounted, paraffin-embedded tissue sections were obtained for each tissue sample
analyzed for BRCA1 mutations. Three 5 min. xylene baths followed by hydration in a
descending concentrations of alcohol dip (100%, 95%, 70% and water) was used initially
to deparaffinize each sample. Slide mounted tissue sections were then placed in a 0.01 M
citrate buffer (pH 6.0) and microwaved for 10 min. at low power followed by a
deionized, distilled-water rinse and a 30 min. treatment in 1% H2O2. Tissue was then
washed in lOmM phosphate buffer saline solution (PBS) and treated for 20 min. with
blocking solution antigen (BSA) (1% BSA/PBS , 3 drops goat serum). Excess blocking
solution was removed and one of the two primary antibodies was applied.
Antibody-treated sections were incubated at room temperature for one hour. The
two primary antibodies used were C-20 and D-20 (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA). Each are affinity-purified, rabbit, polyclonal antibodies raised against a
peptide corresponding to the amino acid sequence at opposite ends of the BRCA1
protein. The C-20 antibody corresponded to the carboxy terminus of the BRCA1 protein
and the D-20 corresponded to the amino terminus. A biotinylated, affinity-purified, anti¬
immunoglobulin supplied in the Vectastain ABC Kit (Vector Laboratories, Inc.) was
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applied as a secondary antibody. Both primary and secondary antibodies were diluted
with PBS to a range of 0.5-1.0 ug/ml and 5-10 ug/ml, respectively. Elucidation of
antibody binding was realized with the precipitation-producing chromogen diaminobenzidine tetrahydrochloride (DAB) followed by hematoxylin counterstaining or
3-amino-9-ethylcarbazole (AEC) with an eosin counterstain according to the
manufacturers’ supplied protocols. Coverslips were applied to treated tissue samples for
microscopic viewing. The appearance of antibody staining on each treated tissue section
was evaluated visually three times using an optical microscope. Staining intensity,
indicative of antibody reactivity, was noted for each slide as either normal or reduced.

2.6 Results
Among the ten paired specimens analyzed, no change in immunohistochemical
reactivity was detected in four tumors or their related, uninvolved tissues (Table 1.
Figure 2). Mutation analysis employing SSCP revealed no BRCA1 gene alterations
present in any of these four pairs of samples (Table 1). The six remaining pairs
displayed reduced immunohistochemical reactivity of D20 and C20 in only tumor tissue
(Table 1, Figure 2). DNA mutation analysis for these tumor specimens, using SSCP,
showed a reduction in bands for many exons of the BRCA1 gene relative to their
uninvolved normal tissue. This was interpreted as allelic loss of multiple intragenetic
areas within the BRCA1 gene for each of these tumors. This is consistent with the high
occurrence of LOH reported for ovarian tumors. The remaining four normal tissue
samples were immunohistochemically normal.
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Two uninvolved normal tissue samples associated with this group showed a reduction in
C20 antibody (Table 1, Figure 2). No BRCA1 gene alterations were detected in this
latter group of four. However, a germline BRCA1 mutation was detected in each of the
two former normal tissue samples that expressed reduced C20 antibody reactivity (Table
2, Figure 2). Germline BRCA1 mutations found in these two normal uninvolved tissue
samples were characterized as insertions. Both mutations produced a truncated BRCA1
protein (Table 3).
The sensitivity (number testing positive/true positives X 100) and specificity
(number testing negative/true negatives X 100) of this immunohistochemical method for
detection of BRCA1 mutation were each 100%. The positive predictive value (true
positives/ those testing positive X 100) of this method was 100% and the negative
predictive value (true negatives/ those testing negative X 100) was 100%.

TABLE 1
BRCA1 Immunohistochemical Analysis

BRCA1 Mutation Analysis

Number Tumor Tissue Uninvolved Tissue Tumor Tissue Uninvolved Tissue
Of Samnles D20 C20
D20 C20
no mutations detected
4
normal normal normal normal
LOH
none detected
4
normal normal
LOH
germline mutation
2
J.
i
normal
J.

l

l

Table 1. BRCA1 Immunohistochemical analysis and mutation analysis of surgical
specimens of ten paired samples of ovarian tumors and normal, uninvolved tissues.
■ = reduced antibody reactivity. LOH = loss of heterozygosity.
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Sample
A
B
C
D
E
F

TABLE 2
BRCA1 SSCP Mutation Analysis- aberrant band locations
Ovarian tumor
Paired normal tissue
9,11c. 1 Id. 13.17.18. 20
none
9. 11c. lid. 15.22.24
none
2.4. 11a. lib. 15.18.22.24
none
7,11c. lid. 13.15.16
none
p
12.13,15.21.22.24
13,15. 17. 18.22.24
15

Table 2. BRCA1 SSCP mutation analysis of 6 paired surgical specimens of matched
ovarian tumors and normal uninvohed tissues. A-F. Exons are identified where
reductions in allelic bands for the BRCA1 gene were revealed for six ovarian tumors
and location of two germline BRCA1 mutations in paired normal tissue.

Characterization of 2 Germline BRCA1 Mutations
Identified In Surgical Specimens of Normal Tissue
Exon 12 - "g~ insen at nucleotide site 4167. Frameshift starts at
codon 1389Resulting in GTA to TAA i stop) at exon 12 13 splice site.
Expected sequence: C AG AGT GAC ATT
Actual sequence:
CAG AGT GAG CAT
Exon 15 - Two ~c~ insertions at nucleotide sites 54325 and 54328.
Frameshift starts ai codon 1532 resulting in TGA (stop) at codon 1548.
Expected sequence: GAT GTG GAG
Actual sequence:
GAC TGT CGG

Table 3. Characterization of tw o germline BRCA1 mutations identified in
surgical specimens of normal tissue. Tissue samples were from paired surgical
specimens of ovarian tumors and uninvoh ed normal tissues selected from a
population at high-risk for earning a germline BRCA1 mutation
2.7 Discussion
BRCA1 gene mutations are associated with approximately half of all ovarian
cancers, with BRCA1 germline alterations representing five to ten percent of this
population This analysis of ten high-risk ovarian cancer patients was consistent with
these findings. Six of ten malignancies examined could be attributed to BRCA1 gene
mutations and two paired samples were found to contain BRCA1 germline mutations.

Loss of intragenetic sequences of the BRCA1 gene, determined by a reduction in the
SSCP banding patterns, was found in six of these tumor specimens. LOH of areas in
and around the BRCA1 gene reportedly occurs with great frequency (12, 26-30, 118121, 149, 150, 161-163). This is particularly true throughout chromosome 17 in ovarian
carcinomas.
Although the biological significance of this occurrence has yet to be determined,
identification of areas that harbor tumor-suppressor genes have been identified by the
presence of LOH using restriction-fragment-length-polymorphism analysis (57, 154)
In this study, antibodies were used to detect specific regions of the BRCA1
protein. Earlier, the use of different antibodies and techniques resulted in conflicting
results reported by some research groups (40, 45, 48, 49). There has been some
resolution to the debate centered on the subcellular location of the BRCA1 protein in
tumor and normal breast cells alike. Smaller BRCA1 protein products have been found,
along with their mRNA splice variants, in different cell types (18, 44). Additionally,
there is evidence for a nuclear localization signal in normal BRCA1 protein. Proteinprotein interactions may also be required for translocation of the BRCA1 protein to the
nucleus (40). Certain domains of the BRCA1 protein are key sites of biological activity
and are found in all splice variations. Two of these are the amino terminal zinc finger
region and the carboxy end. These findings have allowed a better understanding of how
specific site mutations may lead to variations in subcellular location of BRCA1 protein
and also help explain conflicting results.
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One fact that is not in contention, however, is that approximately 90% of all BRCA1
mutations lead to alterations resulting in the introduction of a premature stop codon (6).
The product is a truncated BRCA1 protein that does not contain the carboxy terminal.
The goals of the present study were to determine whether immunohistochemistry
could serve as a tool for detecting LOH of the BRCA1 gene in surgical specimens of
ovarian tumors and similarly, for detecting germline mutations, which result in BRCA1
protein truncations, in normal surgical specimens.
In this study immunohistochemical interpretations strongly correlated with the
presence or absence of BRCA1 gene mutations. The high sensitivity, specificity, and
positive and negative predictive values observed suggest that immunohistochemistry
may serve as a useful tool in the detection of BRCA1 gene alterations and mutations in
frozen surgical specimens. Additionally, immunohistochemistry is significantly less
expensive and less labor intensive than current DNA analysis further adding to its utility.
BRCA1 immunohistochemical characterization may also prove useful in enhancing
our understanding of the pathogenesis of ovarian cancer. This method may prove
valuable in the molecular characterization and grading of ovarian tumors and aid in the
development and administration of more specific therapies. This method may also aid in
the rapid and inexpensive detection of germline mutations in normal surgical specimens.
This may be particularly important for families wishing to determine their risks of
heritable breast/ovarian cancer, in which the only informative, biologic source for gene
characterization is archival tissue of affected, deceased relatives.
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Above, Tumor Specimens

Above, Normal Uninvolved Tissue

Figure 2. Surgical specimens of paired ovarian tumor and normal uninvolved
tissue. Slide mounted, thin sections. Samples stained with a BRCA1 antibody,
D20 amino antibody or C20 carboxy antibody. Antibody expression indicated
by red-brown color. Top row,normal expression. Middle row, reduced D20
and C20 expression in tumor tissue only. Bottom row, reduced D20 and C20
expression in tumor, reduced C20 in normal tissue.

36

CHAPTER 3
IMMUNOHISTOCHEMICAL ANALYSIS OF BRCA2 EXPRESSION IN
HUMAN BUCCAL CELLS
3.1 Overview
Cytospin deposited human buccal cells were studied for BRCA2 expression.
Protein expression was detected with two goat polyclonal antibodies (Santa Cruz
Biotechnology, Inc), 1-17 to the amino terminal and C-15 to the carboxy terminal of
human BRCA2. Both antibodies distributed to the nuclear and cytoplasmic compartment
of the cells. Greatest reactivity was seen in the cell nucleus. Approximately 30% - 40%
of cells displayed positive antibody reactivity. Earlier, buccal cells were assayed with
BRCA1 antibody. Approximately 85% - 90% of cells showed positive reactivity. RTPCR studies of human buccal cell mRNA demonstrated levels of BRCA2 gene
transcription consistent with our immunohistochemical findings.

We conclude that

buccal cells may be used as a minimally invasive, normal cell source for which to
conduct immunohistochemical analysis of the BRCA2 protein.

3.2 Introduction
Some 20,000 women diagnosed annually with breast or ovarian cancer are
thought to have been genetically predisposed to contracting this disease (1-4).
Collectively, BRCA1 and BRCA2 account for approximately 90% of heritable breast
and ovarian cancers and for an estimated 1 in 400 sporadic forms of these cancers that
result from somatic mutations in the population at large (1-4). Carriers of a germline
mutation in the BRCA1 or BRCA2 gene are placed at a highly penetrant, autosomal
dominant predisposition to contracting cancer.
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These genetic lesions confer an 85% lifetime risk of contracting breast cancer,
whereas 12.5% is the normal rate of occurrence in the general population (1-4).
Mutations in each of these genes confer different levels of susceptibility to
various types of cancer. BRCA1 mutations are found in high frequency in families with
both breast and ovarian cancer and relatively low frequency in site-specific breast
cancers, while a 3 and 4-fold increased risk is reported for prostate and colon cancers
respectively (3, 5). BRCA2 mutations are found in highest frequency in female breast
cancer and lower frequency in ovarian cancers. BRCA2 has also been associated with
male breast, prostate and laryngeal cancers as well (3).
Using antibodies raised against specific gene products has provided much
information about conditions and kinetics of the induction of gene expression. Such is
the case with the BRCA2 gene. Immunohistochemical analysis has allowed localization
of the BRCA2 protein to subcellular regions and has aided in the elucidation of critical
regions of protein interactions. This information has provided clues to the biological
functions of the BRCA2 protein and helped detail regulatory pathways and define the
overall functional roles for this tumor suppressor gene.
Similar to BRCA1, BRCA2 has clearly been shown to be cell cycle regulated
with induction occurring in late G1 early S phase of the cell cycle (77, 79-83). Patterns
of RNA expression for both BRCA1 and BRCA2 were similar during the proliferation
phase of the cell cycle while transcripts from each gene were not detected in quiescent
cells.
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One critical area identified on the BRCA2 protein is the active binding site
located at the amino terminal on exon 3. This site shows transcriptional activation
potential with BRCA2 residues 290-453 interacting with a transcriptional co-activator
protein, P/CAF (123). The N-terminal region of the BRCA2 protein also appears to have
the capacity to activate transcription. Although this regional role is not clearly defined,
amino acid segments within this region of BRCA2 are similar to the JNK-docking site
found in the JUN protein. This JNK-docking site reportedly plays a regulatory role in
transcription activation (124).
Interaction between the BRCA2 protein and RAD51 clearly suggests BRCA2 is
also a component of the DNA damage response pathway (88, 125, 126). This is based
on earlier findings reported for the product of another tumor suppressor gene, the p53
protein, and the RAD51 protein. These are two well-known components of the DNA
damage response pathway (130, 131). BRCA2 interacts directly with RAD51 through
two binding sites. One site is located in the N-terminal region encoded by exon 11. The
second, the c-terminal region of the BRCA2 protein (88, 86, 109, 114). Recently, a 460Kda nuclear BRCA2 phosphoprotein was reported to form in vivo complexes with both
p53 and RAD51. Also, exogenous BRCA2 expression in cancer cells inhibited
transcriptional activity of p53. RAD51 coexpression reportedly enhanced the inhibitory
effect (127). The importance of the BRCA2 protein’s COOH terminus (amino acids
3140-3328) to RAD51 mediated DNA repair was shown by analysis of cultured cells
with a deletion of this region. Cells of this type were hypersensitive to gamma-radiation
but were not sensitive to UV light. These cells also maintained the G1 -S and G2-M
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checkpoints after exposure. This suggests defective recombination repair while
nucleotide excision repair remained intact. Cell cycle for COOH-deleted cells was
maintained at a similar rate as wild type cells.
However, these mutated cells underwent senescence more rapidly. This data
supports the hypothesis that deletion of BRCA2 allows for cancer development by
defective RAD51 -mediated DNA repair and not by defective cell cycle regulation (86,
112, 128, 129).
BRCA2 expression has been reported in testis using multiple tissue northern
(MTN) filters probed with PCR product. Also, RT-PCR analysis showed that BRCA2
transcription occurs in brain, breast, kidney, lung, leukocytes, ovary, pancreas, prostate,
spleen, stomach and thymus (14). The BRCA2 protein has also been shown to undergo
differential splicing, giving rise to a novel variant protein called BRCA2a. This splice
variant lacks a putative transcriptional activation domain. Levels of expression for both
BRCA2 and BRCA2a protein are differentially expressed. High expression for both
splice variants is found in the thymus and testis and low to moderate expression is found
in mammary gland and prostate. Varying levels of expression of these splice variants
have been interpreted to indicate that each has a role in the development and
differentiation of cells comprising these tissues (122).
Previously, we demonstrated that BRCA1 protein was expressed in normal
human cells, which were obtained by a minimally invasive method, from the oral buccal
cavity (233). BRCA1 protein reactivity was detected by immunohistochemistry with
three commercially available antibodies, D20 (Santa Cruz Biotechnology), MSI 10 and
MS 13 (Oncogene). Distribution of BRCA1 protein was both cytoplasmic and nuclear,
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and was present in about 80% of buccal cells. These cells provide a healthy, easily
accessible model system in which to study intracellular mechanisms of BRCA1 protein
action.

3.3 Hypothesis
Buccal cells are a rapidly proliferating epithelial cell population that would be
expected to contain randomly cycling cells, both positive and negative, for expression of
the BRCA1 and BRCA2 protein. This was observed for the BRCA1 protein. Given the
many similarities between expression of the BRCA1 and BRCA2 protein, the hypothesis
of this study is that human buccal cells will transcribe the BRCA2 gene and express the
BRCA2 protein.

3.4 Objective
The present study sought to determine whether BRCA2 transcription occurs
within human buccal cells and whether the BRCA2 protein expression can be detected in
this cell source. To accomplish this, total mRNA was extracted from a sample of human
buccal cells and RT-PCR (reverse transcription-polymerase chain reaction) performed
for the BRCA2 gene. Protein expression of the BRCA2 protein was examined with
antibodies directed at the BRCA2 amino and carboxy terminals.
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3.5 Materials and Methods
3.5.1 RT-PCR analysis.
Total buccal cell RNA was extracted with RNAgents, Total RNA Isolation
System Kit Z5110 (Promega, Madison, WI). Pelleted buccal cells from a fresh pooled
sample were treated with 1 ml pre-chilled denaturing solution (25 g guanidine
thiocyanate in 33 ml citrate/sarcosine/b-mercapthoethanol, CBS buffer) for 5 minutes.
Cells were lysed by aspiration with a sterile Pasteur pipette, and 800 ul of 2 M sodium
acetate was then added. Reverse transcription was carried out with a GeneAmp RNA
PCR Kit N808-0017 (Perkin Elmer Cetus, Foster City, CA) following the protocol
supplied by the manufacture. Thereafter, each cDNA sample was amplified for 20
cycles using BRCA2 primers B2#F9833 (5’- CGTACACTGCTCAAATCATTC) and
B2#R10061 (5’- GACTAACAGGTGGAGGTAAAG) (4). Samples were then diluted
10-fold and a BRCA 2 cDNA amplicon spanning the last splice junction was amplified
using 5 ul aliquots (4). Thirty cycles were completed using primers B2#F9857 (5’GTACAGGAAACAAGCTTCTGA) and B2#R10061 once again. Primers were
synthesized by Midland Certified Reagent Co., Midland, TX. Initial PCR conditions
were: a single denaturing step of 95 C (1 min); 20 cycles of 96 C (6 sec), 55 C (15 sec),
72 C (1 min). Secondary PCR-amplification conditions differed only by an increase in
the number of cycles that were used. Primer sequences and PCR amplification
conditions were described in Tavtigian et al. (4). Final PCR product was excised from a
1% agarose gel to remove extraneous primary product. Product was cleaned and
concentrated with Qia quick PCR Purification Kit 28104 (Qiagen, Santa Clarita, CA) for
better visualization, followed by gel electrophoresis in 1% agarose, 0.5X TBE buffer.
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PCR product was visualized by ethidium bromide reaction over a UV light source.
Controls were: RT positive control-pAW109 (308bp), RT negative control-no reverse
transcriptase added, RT and PCR negative controls-water, and PCR positive control-cord
blood DNA used. All controls were carried through PCR amplification.
Cloned DNA sizes were estimated relative to their migration against a 123 bp
ladder (Gibco, BRL, Gaithersburg, MD).

3.5.2 Buccal cell immunohistochemistry:
Buccal cells were collected from the oral cavity of normal male and female adult
donors with cotton swabs moistened with water. Donors were in good health and had no
personal or family history of cancer. Buccal cells were obtained by having the test
subject vigorously rub the inner cheek with a cotton swab, moistened with sterile water,
for approximately 20 seconds on each side. The cotton swab was then submerged in 500
ul of PBS, phosphate buffered saline (PBS: pH 7.5, 0.9% saline, 0.1% crystalline grade
bovine serum albumin) contained in a glass vial and the cells were resuspended by gentle
agitation. Cells from 6 individuals were pooled and counted using a hemocytometer
(Fisher Scientific Co., Pittsburg, PA). The pooled buccal cell sample was diluted to a
final concentration of 32,000 cells/ml PBS. One-half milliliter of buccal cell solution
was cytospin deposited upon Superfrost (Fisher Scientific Co., Pittsburg, PA) precleaned
microscope slides using a programmable cytospin (Shandon Inc., Lemer Laboratories,
Pittsburg, PA) centrifuge. Cells were fixed in a 50:50 acetone:methanol solution, at 20^C for seven minutes. Air-dried slides were stored at -70^C in sealed boxes. Prior to
immunoassay, slides were rinsed twice for 15 minutes in PBS using a mechanical rotator
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for agitation. The rinsed slides were transferred to slide trays having humidified
chamber-type holders that allow the slides to lie flat so reagents may be deposited onto
the region of each slide containing the cells. Excess PBS was removed from each slide
using a suction pipette. Excess blocking solution was also removed and one of the two
primary antibodies to the human BRCA2 protein was applied.
Primary antibodies used were two goat polyclonal antibodies (Santa Cruz
Biotechnology, Santa Cruz, CA); 1-17 to the amino terminal and C-15 to an epitope
located at the carboxy terminal end. No antibody cross reactivity occurs with the
BRCA1 protein. Antibody dilutions and immunoperoxidase assay conditions were as
provided by the supplier. Incubation of antibody-treated sections was modified to one
hour at room temperature followed by overnight incubation at 4 C. A biotinylated,
affinity-purified, anti-immunoglobulin labeled antibody supplied in the Vectastain ABC
Kit (Vector Laboratories, Inc.) was applied as a secondary antibody which binds to the
primary antibody. Both primary and secondary antibodies were diluted with PBS to a
range of 0.5-1 .Oug/ml and 5-10ug/ml, respectively. Elucidation of antibody binding was
realized with the precipitation-producing chromogen di-aminobenzidine
tetrahydrochloride (DAB) followed by hematoxylin counterstaining to display all nuclei
present. This produced brow regions of antibody binding. An alternate precipitant, 3amino-9-ethylcarbazole (AEC), producing blue/black regions of antibody deposition,
was used on some samples followed with an eosin counterstain according to the
manufacturers’ supplied protocols. Coverslips were applied to treated tissue samples for
microscopic viewing.
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Negative control for the BRCA2 polyclonal goat antibodies was preincubation
with excess immunizing peptide obtained from the supplier of the BRCA2 antibodies.
Two additional negative controls were also used. These were substitution of goat IgA
for primary antibody and secondary antibody applied without the application of a
primary antibody. Positive controls were A431 cells, human epidermoid carcinoma
(American Type Culture Collection, Manassas, VA).

3.6 Results
Polymerase chain reaction of reverse transcribed buccal cell RNA and fetal cord
blood DNA produced BRCA2 cDNA products of expected size; approximately 210bp
(Figure 3). Antibody reactivity was positive for the BRCA2 protein in 30% - 40% of
cytospin deposited human buccal cells, for the two antibodies, C-15 and 1-17, used here
(Figure 4). These results were consistent in all samples. Cellular distribution of
immunoreactivity for each BRCA2 antibody was seen in the nucleus and cytoplasm
(Figure 4). Reaction intensity, determined by lighter or darker coloration, was greatest in
the nucleus of most buccal cells.

3.7 Discussion
The BRCA 2 gene is transcribed and the BRCA 2 protein is expressed in normal,
human buccal cells. Detection of the BRCA2 protein in buccal cells can be made with
antibodies directed against the protein’s amino and carboxy terminals. A mixed
population of buccal cell expressing positive or negative reactivity to BRCA2
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antibodies was also seen with BRCA1 antibodies. These results are concordant with
reports stating that both these proteins are expressed in a cell cycle manner (77, 79-83).
While the localization between nuclear and/or cytoplasmic distribution of BRCA1
protein remains questionable, current results for BRCA2 suggest that this protein resides
in the nucleus. Our immunohistochemical analysis in human buccal cells showed
BRCA2 localized strongly to the nucleus. However, antibody reactivity for the BRCA2
protein was also found within the cytoplasm.
Additionally, intracellular distribution patterns using antibodies D20 and C20 for
BRCA1, and 117 and Cl5 for BRCA2, were very similar. While protein activation or
functions may occur at one or more intracellular sites, protein synthesis occurs on the
ribosomes within the cytoplasm. It is therefore reasonable to assume that detection for
both may also be realized within the cytoplasm, prior to transport of the protein to the
cell nucleus.
Reverse transcriptase-PCR for BRCA2 mRNA in human tissue was reported
previously by Tavtigian et al. (4). That study demonstrated BRCA2 mRNA in brain,
breast, kidney, lung, leukocytes, ovary, pancreas, prostate, testes, spleen, stomach and
thymus. In our study, performing RT-PCR for BRCA2 in human buccal cells was
technically challenging. Tiered PCR amplifications and concentration of the end cDNA
product was necessary for detection of BRCA2-PCR product without the use of
radioactive labeling. Reverse transcriptase PCR for BRCA1 in human buccal cells was
not as formidable a task. BRCA1 and BRCA2 mRNA expressions are differentially
regulated by sex hormones. Additionally, antibody expression for the BRCA1 protein
was found in a larger percentage of buccal cells than was BRCA2; 60% vs 40%
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Among possible explanations for low amplification of BRCA2 cDNA are: 1. a low
reserve pool of mRNA, suggesting a different type of functional gene regulation for the
BRCA2 than the BRCA1 gene; 2. the presence of several pools of BRCA2 mRNA in
buccal cells representing various splice variants of this large protein, with primers able to
select for only part of the total; 3. inefficient attachment of the primers to cell BRCA2
mRNA and/or less than optimal PCR conditions. Further studies are required to
determine which, if any, of the above explanations are valid.
We conclude buccal cells may prove to be a minimally invasive cell source with
which to study BRCA2 protein expression and functions.
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Figure 3. BRCA2 cDNA product from
RT-PCR performed on total RNA
extracted from normal human
buccal cells. Lane 1, RT-PCR
negative control-no reverse transcriptase
added. Lane 2, BRCA2 PCR negative
control,water used. Lane 3, BRCA2 PCR
positive control-cord blood DNA used.
Lanes 4 and 5, BRCA2 RT-PCR from RNA
isolated from human buccal cells.
Lane 6, RT-PCR positive controlpAW 109 (308bp) used. Lane 7,
123bp ladder. Lane 8, empty.

Figure 4. Immunohistochemical
analysis of BRCA2 protein in
normal human buccal cells.
1-17 amino terminal antibody.
Top picture. C-15 carboxy
terminal antibody
bottom picture. BRCA2 Protein
antibody reactivity indicated
by red-brown color

CHAPTER 4

A MINIMALLY INVASIVE ANTIBODY-BASED ASSAY DETECTS BRCAI
AND BRCA2 PROTEIN TRUNCATIONS INDICATIVE OF THE PRESENCE
OF GERMLINE MUTATIONS
4.1 Overview
Mutations in BRCAI and BRCA2 reportedly account for 90% of predisposed
women diagnosed with breast or ovarian cancer each year. Approximately 4% of
women of reproductive age have a significant family history. Still other mutation
carriers reportedly lack a significant family history of cancer and erroneously believe
they are low risk.
Currently, clinical genetic testing employs gene sequencing. This technique,
when used clinically, is expensive and time consuming. Earlier, we reported on
developing an antibody-based assay that correlated with BRCAI germline alterations in
surgical specimeas from individuals with ovarian cancer. Subsequently, buccal cells
were analyzed for their utility as a minimally invasive cell source for this assay. Results
of RT-PCR showed that the BRCAI and BRCA2 genes are traascribed in buccal cells.
Protein expression was confirmed for each gene using immunohistochemical techniques.
Here we present the results of a double blind study of 13 highly selected, at risk
individuals. Mutation analysis and/or direct sequencing were conducted on BRCAI
and/or BRCA2 for each individual. Buccal cells were also collected from each patient
and were ased to conduct an antibody-based assay in which the amino and car boxy
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terminals of the BRCA1 and BRCA2 proteins were detected. In 12 of these cases, the
antibody-based assay correctly predicted the presence or absence of a BRCA1 or
BRCA2 germline mutation. For the remaining individual, the immunohistochemical
analysis did not correlate with sequencing results and may be a false positive. The
negative predictive value of this assay was 100%. The positive predictive value was
approximately 90%. These results suggest that a simple, antibody-based assay, may
serve as a rapid, minimally invasive and inexpensive clinical tool for screening
individuals for BRCA1 and BRCA2 mutations that result in protein truncations.

4.2 Introduction
Heritable BRCA1 and BRCA2 mutations are reported to collectively account for
90% of predisposed women diagnosed with breast or ovarian cancer (1-4). Germline
mutations in the BRCA1 or BRCA2 gene place these individuals at high risk of
contracting various cancers. These genetic lesions confer up to an 85% lifetime risk of
contracting breast cancer, whereas the normal risk of occurrence is estimated at 12.5% in
the general population (1-4).
For both of these two genes a mutation confers different levels of susceptibility to
breast and to ovarian cancer, as well as to some other types of cancer. BRCA1 mutations
are found in high frequency in families where both breast and ovarian cancer has
occurred, and relatively low frequency in site-specific breast cancers. Also, a mutation
to this gene reportedly increases risk for prostate and colon cancers 3 and 4-fold,
respectively (3, 5).
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In contrast to BRCA1, BRCA2 mutations are found in highest frequency in
female breast cancer and in lower frequency in ovarian cancers. BRCA2 alterations are
also associated with male breast cancer and other site-specific cancers (3, 10). Recently,
DNA analysis was conducted on 112 families. Each family contained a minimum of 2
cases of epithelial ovarian cancer. All cancer cases were accounted for by mutations in
these two genes. Additionally, germline mutations were four times more common in the
BRCA1 gene than BRCA2. No evidence for other susceptibility genes was found,
leaving a high probability that BRCA1 and BRCA2 mutations may be responsible for all
familial ovarian cancer (168).
Some ethnic populations contain high frequencies of specific mutations in
BRCA1 and BRCA2 (6). However, the vast majority of mutations reported to date are
distributed over their whole coding sequences. In BRCA1, over 500 mutations have
been identified. This list includes missense mutations, frameshifts, splice-site alterations
insertions and large deletions (2, 7, 11-14, 38). In BRCA2, however, the majority of
mutations described involve microdeletions of 1-6 nucleotides. These have resulted in
missense and frameshift mutations only (4). This large assortment of mutations, coupled
with the formidable size of each of these genes, makes detecting mutations and gene
sequencing very labor intensive, expensive and technically challenging.
Large genomic rearrangements and deletions are common features of many
human diseases, many of which are not detected by conventional screening procedures
(11-14). This has also been shown with BRCA1 and BRCA2. Several large germline
deletions in BRCA1 and 1 germline deletion in BRCA2 were reportedly undetected by
conventional genomic screening procedures (169, 172, 174).
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Alternative methods of mutation detection have been reported for the BRCA
genes, among others, in order to develop simple yet reliable screening procedures that
are affordable to the general public. One commercial laboratory reported testing for
BRCA1 using a phase test approach. This consists of an allelic-specific oligonucleotide
assay for the 8 most common BRCA1 mutations, a protein truncation test for exon 11
and direct sequencing of the remaining genomic regions (175). For p53 mutation
analysis a modified nonradioactive PCR-SSCP is reported to be faster, easier and less
expensive to perform than conventional methods, and it yields equivalent results (176).
A potential diagnostic test for lung cancer that does not involve gene sequencing was
also reported. This involves examining bronchial epithelial cells for loss of
heterozygosity (LOH) (177). Loss of heterozygosity is commonly reported for BRCA1
and BRCA2 (12, 26-30, 41, 56, 57, 70, 118-121, 149, 150). Reportedly, 88% of
informative tumors (157-161) and 40% of sporadic tumors (162-164) show LOH for the
BRCA loci. However, this reportedly has little clinical diagnostic value and no
prognostic value relative to the BRCA genes (178).
Structurally, both of these genes have much in common: a translational start-site
for each gene is located in exon 2; exon 11 contains over 50% of the codons for the
amino acid sequence; and both genes code for an exceptionally large, highly charged
protein (3).
Another feature common to most BRCA1 and BRCA2 gene mutations is that
they produce a truncated protein as a result of prematurely introducing a stop codon in
their amino acid sequence (8).
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Earlier, using antibodies directed against the expected amino and carboxy
terminals of the BRCA1 protein in surgical specimens, we were able to identify patients
with germline BRCA1 mutations. Approximately 90% of BRCA1 mutations result in
protein truncations. These shortened proteins do not contain a carboxy terminal.
Individuals with only one functional allele were identified by reduced antibody
expression of this carboxy terminal relative to antibody reactivity to their amino
terminal. Results were confirmed with mutation analysis and DNA sequencing.
Buccal cells were then studied as a possible minimally invasive cell source for
this assay. Immunohistochemistry and RT-PCR for BRCA1 and BRCA2 confirmed
transcription, translation and expression of each protein in normal human buccal cells (9,
unpublished results).
Here, we undertook to develop a minimally invasive, inexpensive screening test
for BRCA protein truncations by utilizing buccal cells in an antibody-based assay. To
accomplish this, a double-blind study of 13 highly selected, at risk individuals were
screened for germline BRCA mutations using this antibody-based assay and mutation
analysis and/or direct DNA sequencing of the BRCA1 and/or BRCA2 gene.

4.3 Hypothesis
We hypothesized that a germline BRCA1 or BRCA2 mutation resulting in a
protein truncation would be detected in human buccal cells.
This would be visually evident by a 50% reduction in antibody reactivity to their
respective carboxy termini, when compared to their amino termini, for carriers of a
germline mutation. Noncarriers would not display a reduction in antibody reactivity.
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4.4 Objectives
To test this hypothesis the objectives were: 1. following signed consent, collect
buccal cells and whole blood specimens from thirteen high-risk patients for carrying a
germline BRCA mutation; 2. Conduct a double blind study consisting of mutation
analysis and/or direct sequencing of the BRCA1 and BRCA2 genes, and
immunohistochemical analysis of buccal cells.

4.5 Materials and Methods
4.5.1 Buccal Cell Immunohistochemistry
Following signed consent, buccal cells were collected from the oral cavity of male
and female adult donors with cotton swabs moistened with sterile water. Cells were
obtained by having the test subject vigorously rub the inner cheek with a cotton swab
moistened with sterile water for approximately 20 sec. on each side. The cotton swab
was then submerged in 500 ul of phosphate buffered saline (PBS: pH 7.5, 0.9% saline,
0.1% crystalline grade bovine serum albumin). Cells were counted using a
hemocytometer (Fisher Scientific Co., Pittsburgh, PA). The buccal cell sample was
diluted to a final concentration of 32,000 cells/ml PBS. One-half milliliter of buccal cell
solution was cytospin deposited upon Superfrost (Fisher Scientific Co., Pittsburgh, PA)
precleaned microscope slides using a programmable cytospin (Shandon Inc., Lemer
Laboratories, Pittsburgh, PA) centrifuge. Cells were fixed in a 50:50 acetone:methanol
solution at -20^C for seven minutes. Air-dried slides were stored at -70^C in sealed
boxes. Prior to immunoassay, slides were rinsed twice for 15 minutes in PBS using a
mechanical rotator for agitation. The rinsed slides were transferred to slide trays
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containing humidified chamber-type holders that allow the slides to lie flat so reagents
may be deposited onto the region of each slide containing the cells. Excess PBS was
removed from each slide using a suction pipette. Slides were then treated for 20 min.
with blocking solution (1% BSA/PBS, 3 drops goat serum). Excess blocking solution
was removed and one of the two primary antibodies was applied to the human BRCA1
or BRCA2 protein.
The 2 primary antibodies used for BRCA1 were C-20 and D-20 (Santa Cruz
Biotechnology, Inc., CA). Each are affinity-purified, rabbit, polyclonal antibodies raised
against a peptide corresponding to the amino acid sequence at opposite ends of the
BRCA1 protein. The C-20 antibody corresponds to the carboxy terminus of the BRCA1
protein and D-20 to the amino terminus. For BRCA2, primary antibodies used were two
goat polyclonal antibodies (Santa Cruz Biotechnology, Inc.). 1-17 to the amino terminal
and C-15 to the carboxy terminal end. No antibody cross reactivity occurs between the
BRCA1 and BRCA2 protein antibodies.
Antibody dilutions and immunoperoxidase assay conditions were as provided by
the supplier. Incubation of antibody-treated sections was modified to one hour at room
temperature followed by overnight incubation at 4 C. A biotinylated, affinity-purified,
anti-immunoglobulin labeled antibody supplied in the Vectastain ABC Kit (Vector
Laboratories, Inc.) was applied as a secondary antibody which binds to the primary
antibody. Both primary and secondary antibodies were diluted with PBS to a range of
0.5-1.0ug/ml and 5-10ug/ml, respectively. Antibody binding was demonstrated with the
precipitation-producing chromogen di-aminobenzidine tetrahydrochloride (DAB),
followed by hematoxylin counterstaining to display all nuclei present.
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This produced brow regions of antibody binding. An alternate precipitant, 3-amino-9ethylcarbazole (AEC), producing blue/black regions of antibody deposition, was used on
some samples followed by an eosin counterstain according to the manufacturers’
supplied protocols. Coverslips were applied to treated tissue samples for microscopic
viewing. The appearance of antibody staining on each slide containing cytospun
deposited buccal cells was visually evaluated 3 times using an optical microscope.

4.5.2 Mutation Analysis
Criteria for patient selection were based on factors associated with heritable
BRCA mutations; early age of onset, significant family history, and/or Ashkenazi Jewish
ancestry.
Genomic DNA was extracted using Puregene DNA Isolation Kit (Gentra
Systems, Inc.). Briefly, cells were lysed using an anionic detergent while limiting
enzyme activity to preserve DNA. RNA was enzymatically digested and salt
precipitated to remove protein contaminate. Genomic DNA was then isolated by alcohol
precipitation and resuspended in a buffered solution. Optical density was measured at
A260 and A280 using a spectrometer on all DNA extractions to determine DNA quantity
and purity.
For single stranded conformational polymorphism (SSCP) analysis, polymerized
chain reaction (PCR) amplification using genomic DNA was performed with intronbased primers surrounding each of 22 BRCA1 exons. Four overlapping primer sets were
used to examine exon 11. Exons 6 and 7 were amplified as one product. PCR was
carried out in a volume of 50ul containing lug genomic DNA, lOmM Tris-HCl (pH 8.3),
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1.5mM MgCl2, 50mM KC1, 200uM each concentration of dATP, dTTP and dGTP,
20uM dCTP, and luCi of labeled [32P] dCTP (6000 Ci/mmol; Amersham, Chicago).
Each primer was 1 .OuM, and 0.4 units of Amplitaq Polymerase (Perkin Elmer Cetus,
CT) was used in each reaction. Amplification was done using a Perkin Elmer Cetus
9600 thermal cycler. A 46 cycle 3-temperature cycling program was used to generate
PCR product. The program initiates with 1 minute at 95C. Cycles commence with 10
sec. at 95C, 10 sec. at 68C, and 10 sec at 72C. This was repeated for 4 sets of 4 cycles
with 68C descending to 60C in 2C increments every 4 cycles. When 60C was reached,
30 cycles were repeated followed by a single 5 min. period at 72C (7).
A modification of an SSCP protocol described by Epstein et al. (232) was used to
detect BRCAl-gene alterations. A lul aliquot of the PCR product was diluted into 9ul of
denaturing-loading buffer consisting of 95% formamide, lOmM NaOH, 0.05% xylene
cyanol FF and 0.05% bromophenol blue. The lOul mixture was heated to 95C for 10
min. and plunged into an ice bath for rapid cooling. A 3ul aliquot of this solution was
then transferred to a 5% polyacrylamide/bis gel containing 5% glycerol and 0.5X Trisborate EDTA for electrophoresis. Gels were prerun at 30 watts for 30min. before
loading with samples. Upper and lower reservoirs of the gel apparatus contained a 0.5X
Tris-borate EDTA buffer.
Gels were run at room temperature for 130watt hours after which they were
transferred to 3mm chromotography paper, placed in plastic wrap and exposed to
reflection autoradiography film (Biomax MR film, Kodak) for 18 to 24 hours at -70C.
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Genomic DNA sequencing was completed using the Amplicycle Sequencing Kit
(Perkin Elmer Cetus, CT). This is a modified version of the Sanger method (235) for
sequencing double stranded DNA (dsDNA) and does not require subcloning and/or
extensive purification prior to sequencing. Sequencing utilized 33P isotope and was
carried out according to the protocols supplied by Perkin Elmer Cetus. Both forward and
reverse alleles were sequenced for each polymorphism identified by SSCP analysis to
confirm a mutation. Reaction cycling was done in a GeneAmp PCR System 9600
(Perkin Elmer Cetus, CA). Termination reaction cycling conditions used an initial step
of 1 min. at 95C followed by 25 cycles of a 3-temperature cycling protocol; 30 sec. at
95C, 30 sec. at 68C and 1 min. at 72C. Reactions were arrested by the addition of 4ul
stop solution with the same composition as that used for SSCP. Sequencing gels
consisted of 6% to 8% acrylamide/bis solution, IX Tris-borate EDTA and 7M urea. Gel
solutions were passed through a micro filter prior to use. All gel glass plates were
silonized on one side. Gels were prerun for 30 min. with IX Tris-borate EDTA buffer at
60-75watts. Just prior to use, sequencing reactions were denatured by heating to 90-94C
for 3 min. A 3ul sample of the denatured sequence solution was dispensed from each
sequence reaction and loaded onto the gel. Gels were run for 2-3 hours at 60-75 watts,
cooled, then fixed in a 10% acetic acid, 10% methanol solution for 30 min. to remove
urea, and transferred to 3mm chromotography paper. Excess liquid was drained from the
gel surface when removed from the solution to allow for ease of transfer.
Gels were covered with plastic wrap, backed with a second sheet of 3mm
chromatography paper and dried in a gel dryer model 583 (Bio-Rad Laboratories).
Sequence ladders were resolved by autoradiographs through direct contact of dried gels
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to Biomax MR x-ray film (Kodak, Inc. NY). Exposure time was 24-48 hours at room
temperature. Direct BRCA2 gene sequencing was conducted by independent
commercial laboratories at Yale University, New Haven, CT, and Mariad Genetics, Salt
Lake City, UT. Genetic analysis of BRCA1 was confirmed by an independent
laboratory, Retrogen, Forest Hills, CA.

4.6 Results
Mutation analysis of the BRCA1 gene in nine individuals revealed fifteen unique
single stranded DNA conformational migration patterns. When sequenced, nine were
found to be silent polymorphisms and did not change the amino acid composition of the
BRCA1 protein. The six remaining DNA alterations were identified as mutations.
Figure 5 shows a picture of autoradiographic results of mutation analysis using SSCP for
these six samples. DNA sequencing in both sense and antisense direction was used to
identify mutations. Each mutation was confirmed by identifying the complement base
pairs for each aberrant DNA sequence, at the expected location, on the reverse sequence.
Figures 6, 7and 8 show sequencing results for these six mutations. Both forward alleles,
one wild type, one mutated, are shown. Additionally, the wild type allele has been
removed from one chromatogram leaving only the mutated forward allele for viewing.
Discriptively, these mutations consisted of two, single base conversions; C to T
found in exon six and C to G found in exon eleven, one single base G insert located in
exon eleven, and three large deletions identified in exons eleven, fourteen and seventeen.
In the latter three cases, the quality and quantity of PCR product alluded to the
possibility that a large deletion was present. In sample 10a, primers flanking exon
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seventeen, sixteen forward and eighteen reverse, were used to amplify sufficient
quantities of cDNA containing the suspected deletion area. For sample five, additional
primers were also used. These primers flanked the deleted area within exon eleven and
helped to establish an approximate location. The online DNA database sequence locator,
known as BLAST (located at http://www.ncbi.nlm.nih.gov/blast/blast.cgi) was used to
help place the location of the sequences on each side of the deletions. A minimum of
fifty base pairs was used in each search. In each case, 90 -100% homology to regions of
BRCA1 were found for each side. This helped identify the number of nucleotide bases
that were missing from their DNA sequence. Exon eleven contained a 109 base pair
deletion and exon fourteen was missing 144 base pairs. In the third case, all of exon
seventeen and part of intron sixteen were removed. Part of intron sixteen was
incorporated on both sides of exon eighteen. At the would-be splice site of exon
seventeen and eighteen, incorporation of a small part of intron sixteen resulted in a
frameshift and a premature stop, ten codons within exon eighteen. DNA alterations in
each of the other five cases also resulted in the premature introduction of a stop codon
(table 4). Each would result in a truncated BRCA1 protein product.
Immunohistochemical analysis was also conducted on buccal cells collected from
these nine individuals using BRCA1 and BRCA2 antibodies. Three observers recorded
similar results during independent evaluation of immunohistochemical analysis for these
nine samples. Six of these samples displayed a reduction of BRCA1 C-20 antibody to
the carboxy end of the BRCA1 protein (Table 5).
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No reduction in BRCA1 antibody reactivity was observed in the three remaining
samples and the BRCA2 protein appeared unaltered in all nine samples (Table 5).
Antibody reactivity was visualized by precipitant producing a red-brown color within the
cytoplasmic region of the buccal cells that expressed BRCA protein. A reduction in
carboxy terminal antibody reactivity was determined visually by a diminished red-brown
color relative to the reactivity of each amino terminal. Figures 9 and 11 show typical
results for immunohistochemical analysis of buccal cells collected from two individuals:
figure 9, one without a BRCA1 germline mutation; figure 11, one with a BRCA1
germline mutation.
Identifiers were revealed and DNA analysis was compared to results of
immunohistochemical-assay. In each case where a reduction of BRCA 1 C-20 antibody
was recorded in buccal cells, the presence of a germline BRCA1 mutation was also
found in the same individual.
DNA analysis for the four remaining individuals consisted of direct sequencing
of the BRCA1 and BRCA2 gene by a commercial laboratory. Two of these individuals
were blood relatives. Sequencing revealed two unique germline BRCA2 mutations in
three of these individuals. These mutations consisted of a single base deletion coupled
with a base change in exon 16 and a single base deletion in exon 22. In each case, the
BRCA2 alteration resulted in a frameshift in the triplet code for the amino acid sequence
resulting in a stop codon directly after it (Table 4).
The antibody-based assay for BRCA1 and BRCA2 protein was also applied to
buccal cells collected from each of these four individuals. Immunohistochemical analysis
correctly predicted the presence of a germline BRCA2 mutation in three buccal cell
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samples. Antibody reactivity did not correlate with DNA sequencing of the fourth
sample. Reactivity for antibodies to the BRCA1 protein appeared unaltered in all four
samples.

Sample
Number
1

DNA Analysis Mutation Characterization

BRCA1 exon 14 144bp deletion, frameshift starts at codon 1462
Amino acid sequence: expected- QTSQKSSEYPIS...
actualQTSQKSSELY stop

3 BRCA1 exon 11 conversion, c to g codon 382. Stop results at codon 382
Amino acid sequence: expected-KYQGSSVS...
actual- KYQGSSV stop
4 BRCA1 exon 11 single base insert g codon 284. Stop results at codon 285
Amino acid sequence: expected- SSLQHEN...
actual- SSLQ stop
5

BRCA1 exon 11 109bp deletion, frameshift starts at codon 1098
Amino acid sequence: expected- I..KQSLPGSNCKHPEI...
actual- ..IFLEVIVR1LK stop
6

BRCA1 exon 6 conversion, c to t codon 94. Stop results at codon 94
Amino acid sequence: expected- CAFQLDT...
actual- CAF stop
7 No mutation detected
8 BRCA2 exon 16 single base deletion/conversion; codon 2588.
Amino acid sequence: expected- LANGGWLIPSN...
actualLANGGWLFLQ stop
9 No mutation detected

Table 4. Results of DNA analysis of the BRCA1 and BRCA2 gene for thirteen
high-risk individuals for a germline BRCA1 or BRCA2 mutation.
Continued next page
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10a BRCA1 exon 17 deleted. Fifteen bases from part of intron 16 inserted
onto the front of exon 18. Frameshift starts at codon 1691, splice site
of exons 17 and 18. Stop results at codon 1701.
Amino acid sequence: expected- DAEFVCERTLK...
actualMLSLCVNGH stop
10b No mutation detected
11a BRCA2 exon 22 single base deletion results in frameshift. Stop codon
at codon 3026.
Amino acid sequence: expected- ..ANIQLAATKKT.
actual- ..ANIQ stop
lib BRCA2 exon 22 single base deletion results in frameshift. Stop codon
at codon 3026.
Amino acid sequence: expected- ..ANIQLAATKKT...
actual- ..ANIQ stop
Table 4. Continued.
Sample
IMMUNOHISTOCHEMICAL ANALYSIS
Number
BRCA1
BRCA2
Amino D-20 Carboxy C-20
Amino 1-17 Carboxy C-15
normal
normal
reduced
normal
1
normal
normal
normal
normal
2
normal
normal
reduced
normal
3
normal
normal
reduced
4
normal
normal
normal
reduced
normal
5
normal
normal
reduced
normal
6
normal
normal
normal
normal
7
reduced
normal
normal
normal
8
reduced
normal
normal
normal
9
normal
normal
reduced
normal
10a
normal
normal
normal
normal
10b
reduced
normal
normal
normal
11a
reduced
normal
normal
normal
lib

DNA mutation
analysis
germline BRCA1
none found
germline BRCA1
germline BRCA1
germline BRCA1
germline BRCA1
none found
germline BRCA2
none found
germline BRCA1
none found
germline BRCA2
germline BRCA2

Table 5. Results of immunohistochemical analysis of buccal cells for the BRCAland
BRCA2 protein and mutation analysis of the BRCA1 and BRCA2 genes. Matched
samples taken from thirteen high-risk individuals for a BRCA1 or BRCA2 germline
mutation.
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Figures 10 and 12 show a typical BRCA2 buccal cell assay: figure 10, one
without a germline BRCA2 mutation; figure 12, one containing a germline BRCA2
mutation.

4.7 Discussion
Increased knowledge has led to a greater understanding of the root causes and
effects of human diseases. While the maxim, diagnosis precedes treatment, has held true
throughout medical history, knowledge has allowed for the development of better
techniques for detecting, identifying and treating these diseases.
Presently, many procedures are done routinely to detect and diagnose the presence
of certain cancers. Multiscreening serum chemistries and enzymatic tests as well as
noninvasive procedures are used commonly for this purpose. Bone metastases are
detected initially by elevated alkaline phosphatase and serum Ca. Gallium 67 scans are
used to detect and stage lung cancer and lymphomas. A papanicolaou (pap) smear is
taken to screen for cervical cancer. Prostate cancer is checked by elevated acid
phosphatase (tartrate inhibited). Self-examination and mammography are relied upon for
the initial detection of breast cancer. Alpha-fetoprotein levels are used to detect certain
neoplasms such as hapatomas and testicular carcinomas. Increased fiver enzymes
alkaline phosphatase and alanine amino transferase indicate fiver carcinomas, and other
serum immunoglobulins are used to screen for evidence of multiple myeloma. These,
along with ultrasonography, radiologic studies, lymphangiograms and radioisotopic
scans are generally accepted by the public as necessary preventative and/or diagnostic
medical procedures (234).
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Determining an individual's genetic predisposition for one of these cancers
however, has not been embraced by the public. The burden of expense, which is usually
shouldered by the patient, coupled with the real and perceived risks of discrimination,
are partially responsible for this lack of public acceptance.
The antibody-based assay developed here, if used clinically, may help to alleviate
some anxiety surrounding these two issues. Direct patient costs should be nominal and
independent billing should be avoided, thus helping to ensure greater confidentiality of
patient results and greatly reducing their out-of-pocket expenses. Also, while this assay
may be used to determine a patient's BRCA status with surgical specimens or buccal
cells, it should be noted that the vast majority of people are expected to test negative for
a BRCA germline alteration.
Still, some lack of public willingness to determine their individual genetic
predisposition may be due to technological advances in our diagnostic capabilities.
Relative to testing for genetic abnormalities, our ability to diagnose has outpaced our
ability to treat patients successfully. Gene therapies hold much promise for treating
individuals with genetic alterations that place them at risk for cancers and other diseases.
However, these still remain treatments for the future. Therefore, while diagnosis has
always preceded treatment, patients’ willingness to learn their potential medical needs
for the future may be based on an equal ability to control and if necessary, change their
predicted outcome.
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Lane
1 2 3 4 5 6 7

Lane
1 2 3 4 5 6 7

SSCPforBRCAl exon 14.
Sample 1 is in lane 3.

SSCPforBRCAl exon 11 (partial).
Sample 3 is in lane 6.

Lane
1 2 3 4 5 6 7

Lane
1 2 3 4 5 6 7

SSCPforBRCAl exon 11
(partial). Sample 5 is in lane 1.

SSCP for BRCA1 exon 11
(partial). Sample 4 is in lane 1.

Lane

Lane
1 2 3 4 5 6 7

1 2 3 4 5 6 7

SSCPforBRCAl exon 17.
Sample 10a is in lane 1.

SSCP for BRCA1 exon 6.
Sample 6 is in lane 6.

Figure 5. Results of mutation analysis of the BRCA1 gene using single stranded
conformational polymorphism (SSCP). Images are pictures from autoradiographs
of selected exons of the BRCA1 gene. Lane 2 is negative control.
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Deletion

starts,
intron
inserted.

Intron
insertion
a
totga
(stop).

Sample 1 Chromatograms of the BRCA1 gene exon 14, forward sequence.
Top 2 lines, sequence of wild type allele and mutated allele.
Bottom 2 lines, sequence of mutated allele only.

Single
base change

•C7H
Sample 3 chromatograms of the BRCA1 gene exon 11, forward sequence.
Top, sequences of wild type and mutated allele.
Bottom, sequence of mutated allele only.

Figure 6. DNA sequencing results for samples 1 and 3
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Sample 4 chromatograms of the BRCA1 gene exon 11, forward sequence,
Sequence of wild type allele and mutated allele.
Single nucleotide base, g, insertion.
a

Frameshift
results in 'taa'
stop codon.
Sample 5 chromatograms of the BRCA1 gene exon 11 (partial), forward
sequence. Top, sequence of wild type allele and allele containing deletion,
showing where deletion occurs. Middle chromatogram, sequence
of mutated allele. Bottom chromatogram, sequence of mutated allele showing
insertion where frameshift results in stop codon.
\

[

Sample 6 chromatogramss of the BRCA1 gene exon 6 (partial), forward
sequence. Sequence of wild type allele and allele containing
c to t base change. Cag to tag results in stop codon.

Figure 7. DNA sequencing results for samples 4,5 and 6.

Intron 17 wild type allele and
intron sixteen insertion

* Frameshift starts at exon 17/18 splice site,
Normal allele, first 2 codons: at get.

Sample 10a chromatograms of the BRCA1 gene exon 18 (partial), forward sequence.
Top, sequence of wild type allele and allele containing intron 16 insertion.
Bottom sequence shows insertion sequence. Insertion results in frameshift at exon 17/18 splice site.

Figure 8. DNA sequencing results for sample 10a.

Figure 9. BRCA1 immunohistochemical analysis in normal human buccal cells.
No reduction in D-20 or C-20 antibody reactivity. Red-brown coloration within cells is
indicative of antibody reactivity. Left, D-20 antibody reactivity to the amino end of the
BRCA1 protein. Right, C-20 antibody reactivity to the carboxy end of the BRCA1 protein.

Figure 10. BRCA2 immunohistochemical analysis in normal human buccal cells.
No reduction in 1-17 or C-15 antibody reactivity. Red-brown coloration within cells.
Left, 1-17 antibody reactivity to the amino end of the BRCA2 protein.
Right, C-15 antibody reactivity to the carboxy end of the BRCA2 protein.

Figure 11. BRCA1 immunohistochemical analysis in human buccal cells with a BRCAl
germline mutation. Red-brown coloration within cells is indicative of antibody reactivity.
Left, D-20 antibody reactivity to the amino end of the BRCAl protein. Right, C-20 antibody
reactivity to the carboxy end of the BRCAl protein. No reduction in D-20 antibody reactivity,
reduced C-20 antibody reactivity.
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Figure 12. BRCA2 immunohistochemical analysis in human buccal cells with a
BRCA2 germline mutation. Red-brown coloration within cells is indicative
of antibody reactivity. Left, 1-17 antibody reactivity to the amino end of the
BRCA1 protein. Right, C-15 antibody reactivity to the carboxy end of the BRCA2
protein. No reduction in 1-17 antibody reactivity, reduced C-15 antibody reactivity.
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